GHTC issues statement on ending tuberculosis at WHO Executive Board Meeting
Global Health Council supported by the Infectious Diseases Society of America and Global Health Technologies Coalition commends WHO and member states on accelerating efforts to meet TB elimination goals. Despite progress we are not on track to end the TB epidemic by 2030. If progress continues at the current rate, 28 million people will die by 2030 at a global economic cost of $983 billion. New investments by member states in TB R&D coupled with efficient technology assessment and evaluation of new TB products by WHO will be vital to building the arsenal of tools required to control TB.
An estimated 3 million people with active TB infection continue to go undiagnosed and untreated. Countries are too often relying on old technologies, highlighting the need for investments in new drugs, vaccines and rapid molecular and point of care diagnostics, preventive therapies, and shorter, better quality treatments to ensure adherence and mitigate debilitating side effects.
Growing resistance is making TB more deadly and difficult to treat. A new vaccine would be a gamechanger and is critical for addressing growing AMR by reducing the need for antibiotics. As TB is the most prevalent drug resistant infection, strengthening efforts against drug resistant TB is critical for curbing the AMR crisis.